James P Robinson
Overview
Explore the profile of James P Robinson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
2551
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Day C, Grigore F, Hakkim F, Paul S, Langfald A, Weberg M, et al.
Curr Biol
. 2024 Dec;
35(2):354-362.e7.
PMID: 39729988
Serine 31 is a phospho-site unique to the histone H3.3 variant; mitotic phospho-Ser31 is restricted to pericentromeric heterochromatin, and disruption of phospho-Ser31 results in chromosome segregation defects and loss of...
2.
Bhattarai S, Hakkim F, Day C, Grigore F, Langfald A, Entin I, et al.
bioRxiv
. 2024 May;
PMID: 38798502
Background: Heterozygous histone H3.3K27M mutation is a primary oncogenic driver of Diffuse Midline Glioma (DMG). H3.3K27M inhibits the Polycomb Repressive Complex 2 (PRC2) methyltransferase complex, leading to a global reduction...
3.
Day C, Hinchcliffe E, Robinson J
Cells
. 2022 Nov;
11(21).
PMID: 36359771
Histone post-translational modifications modulate gene expression through epigenetic gene regulation. The core histone H3 family members, H3.1, H3.2, and H3.3, play a central role in epigenetics. H3 histones can acquire...
4.
Gewandter J, Dworkin R, Turk D, Farrar J, Fillingim R, Gilron I, et al.
Pain Rep
. 2021 May;
6(1):e895.
PMID: 33981929
Although certain risk factors can identify individuals who are most likely to develop chronic pain, few interventions to prevent chronic pain have been identified. To facilitate the identification of preventive...
5.
Grigore F, Yang H, Hanson N, VanBrocklin M, Sarver A, Robinson J
Neoplasia
. 2020 Jul;
22(9):376-389.
PMID: 32629178
The development of mutant BRAF inhibitors has improved the outcome for melanoma patients with BRAF mutations. Although the initial response to these inhibitors can be dramatic, sometimes resulting in complete...
6.
Philip B, Yu D, Silvis M, Shin C, Robinson J, Robinson G, et al.
Cell Rep
. 2018 May;
23(5):1553-1564.
PMID: 29719265
Isocitrate dehydrogenase 1 (IDH1) is the most commonly mutated gene in grade II-III glioma and secondary glioblastoma (GBM). A causal role for IDH1 in gliomagenesis has been proposed, but functional...
7.
Robinson J, Rebecca V, Kircher D, Silvis M, Smalley I, Gibney G, et al.
Melanoma Res
. 2017 Oct;
27(6):545-557.
PMID: 29076949
Targeted therapies have revolutionized cancer care, but the development of resistance remains a challenge in the clinic. To identify rational targets for combination strategies, we used an established melanoma mouse...
8.
Robinson G, Philip B, Guthrie M, Cox J, Robinson J, VanBrocklin M, et al.
Cancer Res Front
. 2017 May;
2(2):311-329.
PMID: 28480226
Mutations in the metabolic enzyme (IDH) were recently found in ~80% of WHO grade II-III gliomas and secondary glioblastomas. These mutations reduce the enzyme's ability to convert isocitrate to α-ketoglutarate...
9.
Robinson J, Wootton K
J R Nav Med Serv
. 2016 Feb;
101(2):113-5.
PMID: 26867407
The Primary Casualty Receiving Facility (PCRF) Pathology Department was deployed on Operation GRITROCK from October 2014 to April 2015 to support the medical treatment facility on RFA ARGUS. The department...
10.
Cho J, Robinson J, Arave R, Burnett W, Kircher D, Chen G, et al.
Cell Rep
. 2015 Nov;
13(5):898-905.
PMID: 26565903
Metastases are the major cause of melanoma-related mortality. Previous studies implicating aberrant AKT signaling in human melanoma metastases led us to evaluate the effect of activated AKT1 expression in non-metastatic...